A reduced risk of myocardial infarction for RA patients treated with anti-TNF agents compared with conventional DMARDs was also reported in a recently updated analysis of the British Society for Rheumatology Biologic Register (BSRBR-RA) [37]. This evidence concerns the gene TNF and myocardial infarction.